Xenon Pharmaceuticals Inc. — Director's Dealing 2016

May 27, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2016-05-25

Reporting Person: Hayden Michael R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-05-25	Common Shares	M	8230	$3.30	Acquired	18518	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-05-25	Stock Option (Right to Buy)	$3.30	M	8230	Disposed	2016-07-31	Common Shares (8230)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	75886	Indirect
Common Shares	97319	Direct

Footnotes

F1: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F2: The shares subject to the option fully vested on July 31, 2010.

F3: Michael Hayden is the president and principal beneficial shareholder of Genworks Inc.